Drugs online research references
Eur Urol. 1993;24(3):319-26.
Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
Janknegt RA, Chapple CR.
Department of Urology, University Hospital Maastricht, The Netherlands.
Controlled clinical studies have demonstrated that blockade of alpha 1-adrenergic receptors relaxes prostatic muscle tone and decreases the symptoms of benign prostatic hyperplasia (BPH). Doxazosin, a once-daily quinazoline derivative and postsynaptic alpha 1-adrenoceptor antagonist, proven as treatment for hypertension, was evaluated in the treatment of BPH in dosages of 1-16 mg. 456 BPH patients (287 doxazosin-treated and 169 placebo-treated) were evaluated for efficacy and safety in five double-blind, placebo-controlled clinical studies. Doxazosin treatment resulted in improvements in both urodynamic and symptomatic parameters associated with BPH. Efficacy was only assessed in 1, 2 and 4 mg. Adverse experiences were reported in 127 (44.3%) of the patients treated with doxazosin and in 49 (29%) of the patients treated with placebo. Fifteen (5.2%) doxazosin patients and 4 (2.4%) placebo patients withdrew from the studies due to adverse effects. Results from these five clinical trials demonstrate doxazosin is effective and safe and well tolerated in both normotensive and hypertensive patients with BPH.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7505224&dopt=Abstract
Br J Clin Pract Suppl. 1994 May;74:13-7.
Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia.
Pool JL.
Baylor College of Medicine, Houston, Texas 77030.
Hypertension and benign prostatic hyperplasia (BPH) have a number of features in common. For example, both occur with increasing frequency in the elderly, and both are a major source of health expenditure worldwide. However, the most striking feature linking hypertension and BPH is the aetiological role of the sympathetic nervous system. Sympathetic tone mediated by the alpha-receptor is vital in the control of blood pressure. By selectively inhibiting the alpha 1-adrenoceptors in the vasculature, thereby inhibiting the response to epinephrine and norepinephrine and thus reducing peripheral resistance, selective alpha 1-inhibitors such as doxazosin produce a physiological reduction in blood pressure. Receptors of the alpha 1 subtype are also found in the prostate, the urethra and bladder neck. Doxazosin, by reducing the tone of the prostatic smooth muscle, has the potential to improve urinary flow rate, as well as the obstructive and irritative symptoms characteristic of BPH.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7519436&dopt=Abstract
Br J Clin Pract Suppl. 1994 May;74:23-8.
Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
Kirby RS.
St Bartholomew's Hospital, West Smithfield, London, UK.
A number of studies have confirmed the beneficial effects of selective alpha 1-adrenoceptor inhibitors in patients with benign prostatic hyperplasia (BPH). Most produce clinically significant improvements in symptom scores and uroflow, although some of the shorter-acting agents often do so at the expense of adverse events. Doxazosin has a slower onset of action and longer plasma half-life than any other available selective alpha 1-adrenoceptor inhibitor, which may confer advantages in terms of tolerability over the more rapidly absorbed and eliminated selective alpha 1-adrenoceptor inhibitors. Doxazosin produces statistically significant increases in mean and maximum uroflow, as well as small but significant reductions in maximum voiding pressures and statistically significant improvements in symptoms of frequency, urgency, nocturia, reduced uroflow and sensation of incomplete emptying. Changes in uroflow and symptoms are similar in normotensive and hypertensive patients with BPH, and are accompanied in hypertensive patients by a statistically significant fall in blood pressure. Treatment is well tolerated in both normotensive and hypertensive patients. Doxazosin, by virtue of its unique pharmacological profile, is a valuable new treatment option for the many patients with mild to moderate bladder outflow obstruction due to BPH. It may be especially appropriate therapy for those considerable numbers of elderly men who have both hypertension and bladder outflow obstruction due to prostatic enlargement.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7519438&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics